Published in Arch Intern Med on March 22, 2010
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J (2014) 2.31
Natriuretic peptides: Diagnostic and therapeutic use. Indian J Endocrinol Metab (2011) 1.57
The paradox of low BNP levels in obesity. Heart Fail Rev (2012) 1.23
Home monitoring for heart failure management. J Am Coll Cardiol (2012) 1.17
Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One (2013) 1.15
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail (2014) 1.06
Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc (2014) 0.98
Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure. Chest (2011) 0.90
Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure. Syst Rev (2014) 0.80
N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence? Ann Card Anaesth (2016) 0.80
Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev (2015) 0.78
Correlation between B-Type Natriuretic Peptide and Functional/Cognitive Parameters in Discharged Congestive Heart Failure Patients. Int J Endocrinol (2015) 0.78
Biomarkers in cardiology--part 1--in heart failure and specific cardiomyopathies. Arq Bras Cardiol (2014) 0.78
Plasma levels of natriuretic peptides and development of chronic kidney disease. BMC Nephrol (2015) 0.77
The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25). Diabetes Care (2012) 0.77
Natriuretic peptides as biomarkers in heart failure. J Investig Med (2013) 0.77
Increased B-type-natriuretic peptide promotes myocardial cell apoptosis via the B-type-natriuretic peptide/long non-coding RNA LSINCT5/caspase-1/interleukin 1β signaling pathway. Mol Med Rep (2015) 0.76
B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev (2014) 0.75
Chronic heart failure: we are fighting the battle, but are we winning the war? Scientifica (Cairo) (2012) 0.75
The challenges of properly identifying the cause of heart failure hospitalization. Arch Intern Med (2010) 0.75
Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep (2017) 0.75
[The effect of BNP-targeted therapy for cardiac insufficiency: mortality will probably be lowered]. Praxis (Bern 1994) (2010) 0.75
Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs. Crit Pathw Cardiol (2015) 0.75
B-type natriuretic peptide-guided therapy for perioperative medicine? Open Heart (2014) 0.75
Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study. Int J Clin Exp Med (2015) 0.75
Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. Curr Cardiol Rev (2015) 0.75
Can Natriuretic Peptides be Used to Guide Therapy? EJIFCC (2016) 0.75
Analytical performance vs clinical use of natriuretic peptide measurements. Arch Intern Med (2010) 0.75
NT-proBNP: A Guide to Improve the Management of Patients with Heart Failure. EJIFCC (2013) 0.75
Admission hypoxia-inducible factor 1α levels and in-hospital mortality in patients with acute decompensated heart failure. BMC Cardiovasc Disord (2015) 0.75
ACP Journal Club. Review: Therapy guided by B-type natriuretic peptide levels reduces mortality in chronic heart failure. Ann Intern Med (2010) 0.75
B-type natriuretic peptide-guided therapy for chronic heart failure reduces all-cause mortality compared with usual care but does not affect all-cause hospitalisation or survival free of hospitalisation. Evid Based Med (2010) 0.75
The cause of B-type natriuretic peptide elevation and the dose-dependent effect of angiotensin-converting enzyme inhibitor on patients late after tetralogy of Fallot repair. Pediatr Cardiol (2011) 0.75
How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection? Heart Fail Rev (2012) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20
B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18
Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Clinical service organisation for heart failure. Cochrane Database Syst Rev (2012) 1.90
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol (2008) 1.85
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens (2011) 1.80
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension (2010) 1.74
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol (2008) 1.69
Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension (2009) 1.67
Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail (2011) 1.67
Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol (2005) 1.60
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinic-based management of chronic heart failure patients. Eur J Heart Fail (2011) 1.55
Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension (2012) 1.54
Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens (2013) 1.54
Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension (2012) 1.52
Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail (2011) 1.50
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail (2013) 1.49
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail (2012) 1.49
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med (2005) 1.49
Factors associated with deep sternal wound infection and haemorrhage following cardiac surgery in Victoria. Interact Cardiovasc Thorac Surg (2006) 1.48
Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol (2010) 1.48
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging (2003) 1.47
Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension (2002) 1.46
Impaired pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity. Chest (2008) 1.46
Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study. Med J Aust (2006) 1.44
Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation (2007) 1.43
Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: analysis of the Melbourne Interventional Group registry. Eur J Heart Fail (2011) 1.41
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev (2015) 1.41
Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc Drugs Ther (2008) 1.41
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation (2008) 1.39
Amino-terminal-pro-B-type natriuretic peptide levels and low diastolic blood pressure: potential relevance to the diastolic J-curve. J Hypertens (2014) 1.39
Nursing sans frontières: a three year case study of multi-state registration to support nursing practice using information technology. Aust J Adv Nurs (2006) 1.39
Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation (2010) 1.36
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther (2014) 1.34
Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf (2007) 1.31
Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial. J Am Coll Cardiol (2012) 1.31
p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol (2004) 1.28
Sympatho-renal axis in chronic disease. Clin Res Cardiol (2011) 1.26
Losartan increases bradykinin levels in hypertensive humans. Circulation (2005) 1.25
Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail (2011) 1.23
Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J (2010) 1.22
Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res (2012) 1.21
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res (2003) 1.18
Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J (2008) 1.17
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2011) 1.16
Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail (2009) 1.16
B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency department. Circ Heart Fail (2009) 1.16
Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov (2007) 1.15
Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension. Curr Hypertens Rep (2010) 1.14
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol (2010) 1.14
The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep (2012) 1.13
Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem (2005) 1.13
Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol (2011) 1.12
Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". Eur J Heart Fail (2006) 1.10
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J (2003) 1.10
Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One (2012) 1.09
Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors (2003) 1.09
RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther (2013) 1.08
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol (2008) 1.07
Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale and design. Am Heart J (2007) 1.06
Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow. J Card Fail (2004) 1.06
Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther (2010) 1.06
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation (2012) 1.06
Coenzyme Q10 in cardiovascular disease. Mitochondrion (2007) 1.06
Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study. Med J Aust (2007) 1.06